BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 21071697)

  • 1. Ticagrelor effectively and reversibly blocks murine platelet P2Y12-mediated thrombosis and demonstrates a requirement for sustained P2Y12 inhibition to prevent subsequent neointima.
    Patil SB; Jackman LE; Francis SE; Judge HM; Nylander S; Storey RF
    Arterioscler Thromb Vasc Biol; 2010 Dec; 30(12):2385-91. PubMed ID: 21071697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ticagrelor to prevent restenosis: new drug for an old hypothesis?
    Cayla G; Montalescot G; Collet JP
    Arterioscler Thromb Vasc Biol; 2010 Dec; 30(12):2320-2. PubMed ID: 21084699
    [No Abstract]   [Full Text] [Related]  

  • 3. Ticagrelor, but not clopidogrel, reduces arterial thrombosis via endothelial tissue factor suppression.
    Reiner MF; Akhmedov A; Stivala S; Keller S; Gaul DS; Bonetti NR; Savarese G; Glanzmann M; Zhu C; Ruf W; Yang Z; Matter CM; Lüscher TF; Camici GG; Beer JH
    Cardiovasc Res; 2017 Jan; 113(1):61-69. PubMed ID: 28028070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A clopidogrel-insensitive inducible pool of P2Y12 receptors contributes to thrombus formation: inhibition by elinogrel, a direct-acting, reversible P2Y12 antagonist.
    Haberstock-Debic H; Andre P; Mills S; Phillips DR; Conley PB
    J Pharmacol Exp Ther; 2011 Oct; 339(1):54-61. PubMed ID: 21730013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors?
    Delesque-Touchard N; Pflieger AM; Bonnet-Lignon S; Millet L; Salel V; Boldron C; Lassalle G; Herbert JM; Savi P; Bono F
    Thromb Res; 2014 Sep; 134(3):693-703. PubMed ID: 25064036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of the P2Y12 antagonist ticagrelor on neointimal hyperplasia in a rabbit carotid anastomosis model†.
    Sürer S; Toktas F; Ay D; Eris C; Yavuz S; Turk T; Vural AH; Goncu MT; Gul NY; Yalcınkaya U
    Interact Cardiovasc Thorac Surg; 2014 Aug; 19(2):198-204. PubMed ID: 24876217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence of platelet activation at medically used hypothermia and mechanistic data indicating ADP as a key mediator and therapeutic target.
    Straub A; Krajewski S; Hohmann JD; Westein E; Jia F; Bassler N; Selan C; Kurz J; Wendel HP; Dezfouli S; Yuan Y; Nandurkar H; Jackson S; Hickey MJ; Peter K
    Arterioscler Thromb Vasc Biol; 2011 Jul; 31(7):1607-16. PubMed ID: 21512161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model.
    Wang K; Zhou X; Huang Y; Khalil M; Wiktor D; van Giezen JJ; Penn MS
    Thromb Haemost; 2010 Sep; 104(3):609-17. PubMed ID: 20694285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis.
    Gremmel T; Yanachkov IB; Yanachkova MI; Wright GE; Wider J; Undyala VV; Michelson AD; Frelinger AL; Przyklenk K
    Arterioscler Thromb Vasc Biol; 2016 Mar; 36(3):501-9. PubMed ID: 26743169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response variability to P2Y12 receptor inhibitors: expectations and reality.
    Siller-Matula JM; Trenk D; Schrör K; Gawaz M; Kristensen SD; Storey RF; Huber K;
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1111-28. PubMed ID: 24262612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of a novel function-blocking antibody targeted against the platelet P2Y1 receptor.
    Karim ZA; Vemana HP; Alshbool FZ; Lin OA; Alshehri AM; Javaherizadeh P; Paez Espinosa EV; Khasawneh FT
    Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):637-44. PubMed ID: 25593131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose aspirin in dogs increases vascular resistance with limited additional anti-platelet effect when combined with potent P2Y12 inhibition.
    Björkman JA; Zachrisson H; Forsberg GB; von Bahr H; Hansson GI; Warner TD; Nylander S
    Thromb Res; 2013 Apr; 131(4):313-9. PubMed ID: 23419412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P2Y₁₂ and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP.
    Iyú D; Glenn JR; White AE; Fox SC; Dovlatova N; Heptinstall S
    Platelets; 2011; 22(7):504-15. PubMed ID: 21591981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ticagrelor: from discovery to Phase III clinical trial.
    Siller-Matula JM; Jilma B
    Future Cardiol; 2010 Nov; 6(6):753-64. PubMed ID: 21142630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model.
    Ravnefjord A; Weilitz J; Emanuelsson BM; van Giezen JJ
    Thromb Res; 2012 Oct; 130(4):622-8. PubMed ID: 22909827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BF0801, a novel adenine derivative, inhibits platelet activation via phosphodiesterase inhibition and P2Y12 antagonism.
    Zhang S; Hu L; Du H; Guo Y; Zhang Y; Niu H; Jin J; Zhang J; Liu J; Zhang X; Kunapuli SP; Ding Z
    Thromb Haemost; 2010 Oct; 104(4):845-57. PubMed ID: 20806121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ticagrelor for the treatment of arterial thrombosis.
    Gurbel PA; Kereiakes DJ; Tantry US
    Expert Opin Pharmacother; 2010 Sep; 11(13):2251-9. PubMed ID: 20707759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased platelet activation and thrombosis in transgenic mice expressing constitutively active P2Y12.
    Zhang Y; Ye J; Hu L; Zhang S; Zhang SH; Li Y; Kunapuli SP; Ding Z
    J Thromb Haemost; 2012 Oct; 10(10):2149-57. PubMed ID: 22906019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological evaluation of ticagrelor derivatives as novel antiplatelet agents.
    Zhang H; Liu J; Zhang L; Kong L; Yao H; Sun H
    Bioorg Med Chem Lett; 2012 Jun; 22(11):3598-602. PubMed ID: 22546677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet aggregometry and receptor binding to predict the magnitude of antithrombotic and bleeding time effects of clopidogrel in rabbits.
    Wong PC; Crain EJ; Watson CA; Jiang X; Hua J; Bostwick JS; Ogletree ML; Schumacher WA; Rehfuss R
    J Cardiovasc Pharmacol; 2007 May; 49(5):316-24. PubMed ID: 17513951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.